title: Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.
abstract: BACKGROUND
  Continuous complete clinical remission in T-cell acute lymphoblastic leukemia (T-ALL) is now approaching 80% due to the implementation of aggressive chemotherapy protocols but patients that relapse continue to have a poor prognosis. Such patients could benefit from augmented therapy if their clinical outcome could be more accurately predicted at the time of diagnosis. Gene expression profiling offers the potential to identify additional prognostic markers but has had limited success in generating robust signatures that predict outcome across multiple patient cohorts. This study aimed to identify robust gene classifiers that could be used for the accurate prediction of relapse in independent cohorts and across different experimental platforms.
  
  
  RESULTS
  Using HG-U133Plus2 microarrays we modeled a five-gene classifier (5-GC) that accurately predicted clinical outcome in a cohort of 50 T-ALL patients. The 5-GC was further tested against three independent cohorts of T-ALL patients, using either qRT-PCR or microarray gene expression, and could predict patients with significantly adverse clinical outcome in each. The 5-GC featured the interleukin-7 receptor (IL-7R), low-expression of which was independently predictive of relapse in T-ALL patients. In T-ALL cell lines, low IL-7R expression was correlated with diminished growth response to IL-7 and enhanced glucocorticoid resistance. Analysis of biological pathways identified the NF-kappaB and Wnt pathways, and the cell adhesion receptor family (particularly integrins) as being predictive of relapse. Outcome modeling using genes from these pathways identified patients with significantly worse relapse-free survival in each T-ALL cohort.
  
  
  CONCLUSIONS
  We have used two different approaches to identify, for the first time, robust gene signatures that can successfully discriminate relapse and CCR patients at the time of diagnosis across multiple patient cohorts and platforms. Such genes and pathways represent markers for improved patient risk stratification and potential targets for novel T-ALL therapies.
authors.affiliation: Division of Children's Leukaemia and Cancer Research, Telethon Institute for Child Health Research, Perth, Australia.
authors.forename: Amanda L
authors.initials: AL
authors.lastname: Cleaver
authors.forename: Alex H
authors.initials: AH
authors.lastname: Beesley
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Firth
authors.forename: Nina C
authors.initials: NC
authors.lastname: Sturges
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: O'Leary
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Hunger
authors.forename: David L
authors.initials: DL
authors.lastname: Baker
authors.forename: Ursula R
authors.initials: UR
authors.lastname: Kees
mesh_terms: D000293:Adolescent; D000465:Algorithms; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D003663:Decision Trees; D005260:Female; D015870:Gene Expression; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D016328:NF-kappa B / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D020395:Receptors, Interleukin-7 / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D051153:Wnt Proteins / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D016328:NF-kappa B; D020395:Receptors, Interleukin-7; D051153:Wnt Proteins
references.citation: Blood. 2008 May 1;111(9):4477-89
references.pmid: 18285545
references.citation: Leukemia. 2003 May;17(5):887-93
references.pmid: 12750702
references.citation: J Biol Chem. 2001 Aug 17;276(33):31285-95
references.pmid: 11371555
references.citation: Clin Cancer Res. 2005 Nov 1;11(21):7851-60
references.pmid: 16278408
references.citation: Blood. 2003 Oct 15;102(8):2951-9
references.pmid: 12730115
references.citation: Nucleic Acids Res. 2003 Feb 15;31(4):e15
references.pmid: 12582260
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: BMC Cancer. 2006 Sep 26;6:229
references.pmid: 17002788
references.citation: PLoS Med. 2006 Mar;3(3):e47
references.pmid: 16417408
references.citation: J Clin Oncol. 2003 Oct 1;21(19):3616-22
references.pmid: 14512392
references.citation: Leukemia. 2006 Jul;20(7):1197-205
references.pmid: 16688226
references.citation: Leukemia. 1999 Nov;13(11):1696-707
references.pmid: 10557041
references.citation: Leukemia. 2008 Dec;22(12):2142-50
references.pmid: 18818707
references.citation: Leukemia. 2007 Jun;21(6):1198-203
references.pmid: 17410184
references.citation: J Immunol. 2007 Apr 15;178(8):5132-43
references.pmid: 17404296
references.citation: BMC Genomics. 2005 Apr 27;6:59
references.pmid: 15854232
references.citation: Cancer Cell. 2002 Mar;1(2):133-43
references.pmid: 12086872
references.citation: Br J Haematol. 2005 Nov;131(4):447-56
references.pmid: 16281934
references.citation: Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):513-33
references.pmid: 15996891
references.citation: Leuk Lymphoma. 2005 Apr;46(4):483-95
references.pmid: 16019476
references.citation: Prostate. 2007 Jun 15;67(9):955-67
references.pmid: 17440963
references.citation: Nature. 2009 Jun 18;459(7249):1000-4
references.pmid: 19536265
references.citation: Lancet Oncol. 2009 Feb;10(2):147-56
references.pmid: 19147408
references.citation: Blood. 2007 Sep 1;110(5):1429-38
references.pmid: 17495134
references.citation: Blood. 2008 Mar 1;111(5):2548-55
references.pmid: 18039957
references.citation: Cancer Sci. 2004 May;95(5):385-92
references.pmid: 15132764
references.citation: Oncogene. 1995 Oct 5;11(7):1333-8
references.pmid: 7478554
references.citation: Blood. 2002 Jun 1;99(11):4109-15
references.pmid: 12010814
references.citation: Br J Cancer. 2009 Jun 16;100(12):1926-36
references.pmid: 19436302
references.citation: Nat Med. 2007 Jan;13(1):70-7
references.pmid: 17173050
references.citation: Br J Haematol. 2008 Mar;140(6):656-64
references.pmid: 18302714
references.citation: Blood. 2002 Aug 1;100(3):991-7
references.pmid: 12130513
references.citation: Oncogene. 2006 May 25;25(22):3113-22
references.pmid: 16407823
references.citation: Blood. 2000 Jul 1;96(1):297-306
references.pmid: 10891465
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5742-9
references.pmid: 17179108
references.citation: BMC Bioinformatics. 2005 Apr 13;6:97
references.pmid: 15826317
references.citation: Lancet. 2008 Mar 22;371(9617):1030-43
references.pmid: 18358930
references.citation: Cancer Cell. 2002 Feb;1(1):75-87
references.pmid: 12086890
references.citation: Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
references.pmid: 16199517
references.citation: J Cell Sci. 2000 Jul;113 ( Pt 13):2385-97
references.pmid: 10852818
references.citation: Br J Cancer. 2006 Dec 4;95(11):1537-44
references.pmid: 17117183
references.citation: Leukemia. 2009 Jan;23(1):43-52
references.pmid: 18987663
references.citation: Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
references.pmid: 15459662
references.citation: Cancer Res. 2004 Apr 15;64(8):2898-903
references.pmid: 15087409
references.citation: Blood. 2009 Jul 30;114(5):1053-62
references.pmid: 19406988
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7924-9
references.pmid: 19047123
references.citation: Blood. 2007 Oct 1;110(7):2324-30
references.pmid: 17609427
references.citation: Br J Haematol. 2007 May;137(4):319-28
references.pmid: 17456054